Cargando…

Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab

Retinal surface macrophages play key roles in the regulation of immune response, maintenance of vitreous clarity, and tissue repair. We examined the variation of parafoveal surface macrophages in a thyroid eye disease (TED) patient before and after treatment with teprotumumab (Tepezza, Horizon thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otero-Marquez, Oscar, Fayad, Mona, Pinhas, Alexander, Chui, Toco Y. P., Rosen, Richard B., Reddy, Harsha S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844343/ https://www.ncbi.nlm.nih.gov/pubmed/35178261 http://dx.doi.org/10.1155/2022/5275309

Ejemplares similares

3-D OCT angiographic evidence of Anti-VEGF therapeutic effects on retinal capillary hemangioma
por: Otero-Marquez, Oscar, et al.
Publicado: (2022)

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021)

Teprotumumab in advanced reactivated thyroid eye disease
por: Cheng, Olivia T., et al.
Publicado: (2022)

Improvement of asymmetric thyroid eye disease with teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Early experience with teprotumumab for chronic thyroid eye disease
por: Ozzello, Daniel J., et al.
Publicado: (2020)

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
por: Kossler, Andrea Lora, et al.
Publicado: (2022)

Correction: Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Efficacy of CRISPR-Based Gene Editing in a Sickle Cell Disease Patient as Measured through the Eye
por: Pinhas, Alexander, et al.
Publicado: (2022)

Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2021)

The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease
por: Simmons, Brittany A., et al.
Publicado: (2022)

Teprotumumab for thyroid eye disease: early response is not required for benefit
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Teprotumumab in thyroid eye disease: wonder drug or great divider?
por: Perros, Petros, et al.
Publicado: (2023)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

Effects of teprotumumab on patients with long-standing, active thyroid eye disease
por: Vinson, Kyle B., et al.
Publicado: (2022)

Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

A Pilot Study of Subclinical Non-Capillary Peripapillary Perfusion Changes in Thyroid-Related Orbitopathy Detected Using Optical Coherence Tomography Angiography
por: Pinhas, Alexander, et al.
Publicado: (2022)

Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022)

A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease
por: Safo, Myra B., et al.
Publicado: (2021)

Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease
por: Najjar, Wassim, et al.
Publicado: (2022)

Elasomeran/teprotumumab: Thyroid-eye disease flare, diarrhoea and muscle spasms: case report
Publicado: (2022)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
por: Lin, Fei, et al.
Publicado: (2023)

Insights into Sickle Cell Disease through the Retinal Microvasculature: Adaptive Optics Scanning Light Ophthalmoscopy Correlates of Clinical OCT Angiography
por: Pinhas, Alexander, et al.
Publicado: (2022)

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab
por: Bowens, Brendan K., et al.
Publicado: (2022)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study
por: O’Dell, Jordan Miller, et al.
Publicado: (2023)

Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
por: Bocklud, Brooke E, et al.
Publicado: (2023)

Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy
por: Smith, Terry J.
Publicado: (2020)

Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy
por: Adetunji, Modupe O., et al.
Publicado: (2022)

Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases
por: Chiou, Carolina A., et al.
Publicado: (2021)

Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series
por: Chu, Matthew, et al.
Publicado: (2022)

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach
por: Douglas, Raymond S., et al.
Publicado: (2022)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

Human retinal microvascular imaging using adaptive optics scanning light ophthalmoscopy
por: Chui, Toco Y. P., et al.
Publicado: (2016)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease
por: Shah, Kajal, et al.
Publicado: (2022)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2rj2j6shiiecpvut2crlncouom